在大型骨科手术中,因子XI抑制剂与低分子肝素预防静脉血栓栓塞症相比,实现更高疗效且不损害安全性:系统评价与Meta分析
该系统评价与Meta分析纳入4项随机对照试验共2269例患者,比较因子XI抑制剂与低分子肝素在大型骨科手术血栓预防中的疗效与安全性。结果显示,因子XI抑制剂显著降低静脉血栓栓塞症事件(OR 0.50;95%CI 0.36-0.69)及重大或临床相关非重大出血事件(OR 0.41;95%CI 0.22-0.75),输血需求有降低趋势但未达统计学显著(OR 0.69;95%CI 0.32-1.48),不良事件与重大不良事件两组相似。
要点
- 在大型骨科手术患者中,因子XI抑制剂较低分子肝素显著降低静脉血栓栓塞症事件(OR 0.50;95%CI 0.36-0.69)。
- 因子XI抑制剂显著减少重大或临床相关非重大出血事件(OR 0.41;95%CI 0.22-0.75)。
- 输血需求有降低趋势但未达统计学显著(OR 0.69;95%CI 0.32-1.48),不良事件与重大不良事件两组相似。
核心结论
- 在大型骨科手术患者中,因子XI抑制剂较低分子肝素显著降低静脉血栓栓塞症事件及出血事件的发生率。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、CENTRAL和Scopus数据库至2022年5月,纳入4项比较因子XI抑制剂与低分子肝素用于血栓预防的随机对照试验,共2269例患者。
主要发现
- 因子XI抑制剂组静脉血栓栓塞症事件发生率的OR为0.50(95%CI 0.36-0.69),显著低于低分子肝素组。
- 因子XI抑制剂组重大或临床相关非重大出血事件的OR为0.41(95%CI 0.22-0.75),显著低于低分子肝素组。
- 因子XI抑制剂组需输血患者的OR为0.69(95%CI 0.32-1.48),未达统计学显著。
- 两组不良事件与重大不良事件发生率相似。
- 共纳入2269例患者,发生372例静脉血栓栓塞症事件和50例重大或临床相关非重大出血事件。
关键数值与推荐
- 疗效结局包括静脉血栓栓塞症及症状性静脉血栓栓塞症;安全性结局包括重大和临床相关非重大出血事件、重大出血事件、输血需求、不良事件及重大不良事件。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In recent years, many important advances have been seen in anticoagulation therapy. However, bleeding risk is still a major concern. Factor XI (FXI) inhibition has emerged as a potential advantageous target to minimize this risk. OBJECTIVES: We conducted a systematic review and meta-analysis of current evidence on FXI inhibitors for thromboprophylaxis in major orthopedic surgery. METHODS: We performed a systematic search of electronic databases (PubMed, CENTRAL, and Scopus) until May of 2022. Studies were considered eligible if they were randomized controlled trials (RCTs) evaluating FXI inhibitors in thromboprophylaxis versus low molecular weight heparin (LMWH). For analysis purposes, we considered efficacy (venous thromboembolism [VTE], symptomatic VTE) and safety (major and clinically relevant non-major [CRNM] bleeding events, major bleeding events, blood transfusion necessities, adverse events, major adverse events) outcomes. RESULTS: Overall, four RCTs were included, with a total of 2269 patients, 372 VTE events, and 50 major or CRNM bleeding events. Regarding efficacy outcomes, FXI inhibitors were associated with a significant reduction in the incidence of VTE events (odds ratio [OR] 0.50; 95% confidence interval [CI: 0.36, 0.69]). Concerning safety outcomes, FXI inhibitors significantly reduced major or CRNM bleeding events (OR 0.41; 95% CI [0.22, 0.75]). It was also associated with a lower percentage of patients needing a blood transfusion, despite not meeting statistical significance (OR 0.69; 95% CI [0.32, 1.48]). Incidence of adverse events and major adverse events were similar between groups. CONCLUSION: Factor XI inhibitors showed a significant reduction in the incidence of VTE and bleeding events among patients submitted to major orthopedic surgery.
引用
- Presume J, Ferreira J, Ribeiras R, et al. Achieving higher efficacy without compromising safety with factor XI inhibitors versus low molecular weight heparin for the prevention of venous thromboembolism in major orthopedic surgery-Systematic review and meta-analysis. J Thromb Haemost. 2022. PMID: 36128769. doi:10.1111/jth.15890
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。